Characteristics of adverse events of endocrine therapies among older patients with breast cancer

ConclusionsAmong patients ≥ 70 years old, many symptoms were significantly more frequent/severe with AIs than with SERMs, compared with those aged 56–69, which suggests a difference in the profile of adverse events according to the type of endocrine therapy and the patient’s age. It is important to consider the bene fits and risks of each treatment to optimize endocrine therapy for older patients.
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research